CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cadrenal Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cadrenal Therapeutics Inc
822 A1a North, Suite 306
Phone: (904) 300-0701p:904 300-0701 PONTE VEDRA, FL  32082  United States Ticker: CVKDCVKD
Business Summary
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development of tecarfarin, a new phase III-ready oral vitamin K antagonist anticoagulant to address unmet needs in anticoagulation therapy. Tecarfarin is a novel and reversible anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. It is pursuing a product-in-a-pipeline approach with tecarfarin. Tecarfarin has orphan drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including left ventricular assisted devices (LVADs). The Company also has ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). With tecarfarin, it is advancing a solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin, a vitamin K antagonist.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer QuangPham 59 1/25/2022 1/25/2022
Chief Financial Officer Matthew K.Szot 49 1/24/2023 5/17/2022
Chief Operating Officer JeffreyCole 56 2/8/2024 2/8/2024
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 4 (As of 3/13/2025)
Outstanding Shares: 1,940,001 (As of 4/14/2025)
Shareholders: 20
Stock Exchange: NASD
Federal Tax Id: 880860746
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, May 12, 2025